Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors-Reference-Cited by-同舟云学术

Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors

Published:2016-04-04 Issue:19 Volume:7 Page:28059-28074
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Borlak Jürgen¹,Länger Florian²,Spanel Reinhard¹³,Schöndorfer Georg⁴,Dittrich Christian⁵

Affiliation:

1. Centre for Pharmacology and Toxicology, Hannover Medical School, Hannover, Germany

2. Department of Pathology, Hannover Medical School, Hannover, Germany

3. Institute of Pathology, Viersen, Germany

4. Clinical Development, Fresenius Biotech GmbH, München, Germany

5. Applied Cancer Research - Institution for Translational Research Vienna (ACR-ITR VIEnna) and Ludwig Boltzmann Institute for Applied Cancer Research (LBI-ACR VIEnna), Center for Oncology and Hematology, Kaiser Franz Josef-Spital, Vienna, Austria

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors;International Immunopharmacology;2024-09

2. Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors;Molecular Diagnosis & Therapy;2024-08-22

3. IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer;International Immunopharmacology;2024-08

4. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data;Science Advances;2024-05-31

5. Bispecific antibody drug conjugates: Making 1+1>2;Acta Pharmaceutica Sinica B;2024-05